Histopathologic review of prostate biopsies from patients referred to a comprehensive cancer center: Correlation of pathologic findings, analysis of cost, and impact on treatment

Cancer

Volumn 83, Issue 4, 1998, Pages 753-759

  Wurzer, James C ^a   Al Saleem, Tahseen I ^a   Hanlon, Alexandra L ^b   Freedman, Gary M ^a   Patchefsky, Arthur ^a   Hanks, Gerald E ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b NONE

Author keywords

Central pathology review; Gleason score; Perineural invasion; Prostate carcinoma; Prostatic specific antigen

Indexed keywords

ARTICLE; CANCER DIAGNOSIS; CANCER SCREENING; CANCER STAGING; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HUMAN; HUMAN TISSUE; MEDICAL DECISION MAKING; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER;

ADENOCARCINOMA; BIOPSY; HUMANS; MALE; PATHOLOGY, CLINICAL; PROSTATE; PROSTATIC NEOPLASMS;

EID: 0031812382     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980815)83:4<753::AID-CNCR18>3.0.CO;2-R     Document Type: Article

References (25)

1. Gleason DF. Histologic grading of prostate cancer: a perspective. Hum Pathol 1992;23(3):273-9.
2. Partin AW, Kattan MM, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997;277(18):1445-51.
3. Pisansky TM, Kahn MJ, Rasp GM, Cha SS, Haddock MG, Bostwick DG. A multiple prognostic index predictive of disease outcome after irradiation for clinically localized prostate carcinoma. Cancer 1997;79(2):337-44.
4. Spevach L, Killion LT, West JC, Rooker GM, Brewer EA, Cuddy PG. Predicting the patient at low risk for lymph node metastasis with localized prostate cancer: an analysis of four statistical models. Int J Radiat Oncol Biol Phys 1996;34(3): 543-7.
5. Bonin SR, Hanlon AL, Lee WR, Movsas B, al-Saleem TI, Hanks GE. Evidence of increased failure in the treatment of prostate carcinoma patients who have perineural invasion treated with three-dimensional conformal radiation therapy. Cancer 1997;79(1):75-80.
6. Steinberg DM, Sauvageot J, Piantadosi S, Epstein JI. Correlation of prostate biopsy and radical prostatectomy Gleason grade in academic and community settings. Am J Surg Pathol 1997;21(5):566-76.
7. Sogani PC, Israel A, Lieberman PH, Lesser ML, Whitmore WF Jr. Gleason grading of prostate cancer: a predictor of survival. Urology 1985;25(3):223-7.
8. Pilepich MV, Caplan R, Byhardt RW, Lawton CA, Gallagher MJ, Mesic JB, et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol 1997;15(3):1013-21.
9. Ennis RD, Flynn SD, Fischer DB, Peschel RE. Preoperative serum prostate-specific antigen and Gleason grade as predictors of pathologic stage in clinically organ confined prostate cancer: implications for the choice of primary treatment. Int J Radiat Oncol Biol Phys 1994;30(2):317-22.
10. Hanks GE, Lee WR, Hanlon AL, Hunt M, Kaplan E, Epstein BE, et al. Conformal technique dose escalation for prostate cancer: biochemical evidence of improved cancer control with higher doses in patients with pretreatment prostate-specific antigen > or = 10 NG/ML. Int J Radiat Oncol Biol Phys 1996;35(5):861-8.
11. Bostwick DG. Grading prostate cancer. Am J Clin Pathol 1994;102(4 Suppl 1):s38-56.
12. Johnstone PA, Riffenburgh R, Saunders EL, Willison FW. Grading inaccuracies in diagnostic biopsies revealing prostatic adenocarcinoma: implications for definitive radiation therapy. Int J Radiat Oncol Biol Phys 1995;32(2):479-82.
13. Steinberg DM, Sauvageot J, Piantadosi S, Epstein JI. Correlation of prostate needle biopsy and radical prostatectomy Gleason grade in academic and community settings. Am J Surg Pathol 1997;21(5):566-76.
14. Lerner SE, Blute ML, Zincke H. Extended experience with radical prostatectomy for clinical stage T3 prostate cancer: outcome and contemporary morbidity. J Urol 1995;154: 1447-52.
15. Kojima M, Troncoso P, Babaian RJ. Use of prostate-specific antigen and tumor volume in predicting needle biopsy grading error. Urology 1995;45:807-12.
16. Gleason DF. Undergrading of prostate cancer biopsies: a paradox inherent in all biologic bivariate distributions. Urology 1996;47(3):289-91.
17. Jolsolone, Wajsman Z, Huben RP, Wolf RM, Englander LS. Prognostic factors in localized prostate cancer. J Urol 1985; 134:1346-7.
18. De Las Morenas A, Siroky M, Merriam J, Stilmant MM. Prostatic adenocarcinoma: reproducibility and correlation with clinical stages of four grading systems. Hum Pathol 1988;19:595-7.
19. McNeal JE, Villers AA, Redwine EA, Freiha FS, Stamey TA. Histologic differentiation, cancer volume, and pelvic lymph node metastasis in adenocarcinoma of the prostate. Cancer 1990;52:246-51.
20. Oesterling JE, Brendler CB, Epstein JL, Kimball AW Jr., Walsh PC. Correlation of clinical stage, serum prostatic acid phosphatase and preoperative Gleason grade with final pathologic stage in 275 patients with clinically localized adenocarcinoma of the prostate. J Urol 1987;138:92-8.
21. Schroeder FH, Blom JHM, Hop WCJ, Mostofi FK. Grading of prostatic cancer III: multivariate analysis of prognostic parameters. Prostate 1985;7:13-20.
22. Hanks GE, Lee WR, Schultheiss TE. Clinical and biochemical evidence of control of prostate cancer at 5 years after external beam radiation. J Clin Oncol 1995;154:456-9.
23. Epstein JI, Walsh PC, Sanfillipo F. Clinical and cost impact of second-opinion pathology. Review of prostate biopsies prior to radical prostatectomy. Am J Surg Pathol 1996; 20(7):851-7.
24. Bastacky SI, Walsh PC, Epstein JL. Relationship between perineural tumor invasion on needle biopsy and radical prostatectomy capsular penetration in clinical stage B adenocarcinoma of the prostate. Am J Surg Pathol 1993;17:336-41.
25. Aihara M, Truang LD, Dunn JK, Wheeler TM, Scardino PT, Thompson TC. Frequency of apoptotoic bodies positively correlates with Gleason grade in prostate cancer. Hum Pathol 1994;25:797-801.